Infectious Diseases Hub has partnered with Future Virology to bring you exclusive access to articles and features in the recent Special Focus Issue.
Browsing: Drug Development
In a collaborative study between the University of South Florida (USF Health; FL, USA) and the University of Arizona College of Pharmacy (AZ, USA), several existing drugs have been identified as potential therapies for COVID-19.
The emergence and global spread of SARS-CoV-2 has prompted scientific study on an unprecedented scale,…
Rebiotix (MN, USA) recently announced positive preliminary results from an ongoing clinical trial investigating the use of an investigational microbiota-based formulation, RBX2660, for the reduction of C. diff infection.
This month’s research round-up covers a number of studies investigating hydroxychloroquine, along with a remdesivir study, the first Phase I vaccine clinical trial and an exploration of the burden of COVID-19 on the healthcare system.
Take a look at our day-by-day updates covering the latest on therapeutics and vaccines for COVID-19, from new partnerships to clinical trials..
Take a look behind the scenes of a recent Future Virology editorial entitled, ‘An insight into dengue virus proteins as potential drug/vaccine targets’, as we ask author Muhammad Faheem about recent advances in understanding dengue proteins and where the next 5–10 years could take us.
Novel research suggests that some drugs may prevent the acquisition of resistance genes by preventing the induction of bacterial ‘competence’.
Catch up on February’s industry headlines, including an MRSA breakthrough, a patent lawsuit, and the latest updates on the coronavirus outbreak and its impact on the biotechnology industry worldwide.
2020: A molecular odyssey – could artificial intelligence bring in a new age of antibiotic drug discovery?
Using machine-learning, researchers have discovered a new antibiotic that is able to kill bacteria resistant to other antibiotics.